# Nectar Lifesciences (NSE: NECLIFE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NECLIFE · Pivot · prices to 22 Oct 2026

Nectar Lifesciences (NSE: NECLIFE) closed at ₹11.34 on 22 Oct 2026, down 0.09% on the day. With a market capitalisation of ₹220 Cr, it ranks 2209th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −50.3% in FY26. Over the past year the share price has fallen 16.5%. Its 52-week range is ₹9.30 (30 Mar 2026) to ₹22.40 (23 Dec 2025); the last close is 49.4% below the high. Promoters held 51.84% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹11.34 |
| Market cap | ₹220 Cr |
| ROE | −50.3% (FY26) |
| ROCE | −8.7% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹22.40 (23 Dec 2025) |
| 52-week low | ₹9.30 (30 Mar 2026) |
| 1-year return | −16.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | — | — | −₹68 Cr | — | −₹3.38 |
| Q3 FY26 | — | — | ₹14 Cr | +82.0% | ₹0.64 |
| Q2 FY26 | ₹5 Cr | −98.8% | −₹176 Cr | −3,243.0% | −₹7.84 |
| Q1 FY26 | ₹281 Cr | −21.9% | −₹63 Cr | −2,229.0% | −₹2.82 |
| Q4 FY25 | ₹429 Cr | −2.5% | −₹130 Cr | −22,149.2% | −₹5.80 |
| Q3 FY25 | ₹454 Cr | +0.5% | ₹8 Cr | +399.4% | ₹0.35 |
| Q2 FY25 | ₹428 Cr | +7.6% | ₹6 Cr | +449.0% | ₹0.25 |
| Q1 FY25 | ₹359 Cr | −8.8% | ₹3 Cr | +63.2% | ₹0.13 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,670 Cr | −₹114 Cr |
| FY24 | ₹1,684 Cr | ₹5 Cr |
| FY23 | ₹1,524 Cr | −₹24 Cr |
| FY22 | ₹1,669 Cr | ₹25 Cr |
| FY21 | ₹1,543 Cr | −₹73 Cr |
| FY20 | ₹2,366 Cr | ₹32 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 51.84%
- Foreign institutions: 0.50%
- Domestic institutions: 3.74%
- Non-institutions: 43.89%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Nath Bio-Genes (India)](https://app.pivotnow.in/stock/NATHBIOGEN) | ₹132.60 | ₹252 Cr | 6.3 | — |
| [BDH Industries](https://app.pivotnow.in/stock/BDH) | — | ₹252 Cr | — | — |
| [Hannah Joseph](https://app.pivotnow.in/stock/HANNAH) | — | ₹220 Cr | — | — |
| [Syschem (India)](https://app.pivotnow.in/stock/SYSCHEM) | — | ₹214 Cr | — | — |
| [Achyut Health](https://app.pivotnow.in/stock/ACHYUT) | — | ₹209 Cr | — | — |
| [Coral Labs](https://app.pivotnow.in/stock/CORALAB) | — | ₹196 Cr | — | — |

## Questions and answers

### What is the share price of Nectar Lifesciences today?

Nectar Lifesciences (NSE: NECLIFE) last closed at ₹11.34 on 22 Oct 2026. Its 52-week high is ₹22.40 and its 52-week low is ₹9.30.

### What is the market cap of Nectar Lifesciences?

Nectar Lifesciences' market capitalisation is ₹220 Cr (₹220 Cr) at the 22 Oct 2026 close, ranking 2209th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Nectar Lifesciences?

Return on equity was −50.3% in FY26 and return on capital employed was −8.7% in FY26 (consolidated figures).

### Is Nectar Lifesciences a debt-free company?

Nectar Lifesciences is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### How has Nectar Lifesciences stock performed over the last year?

Nectar Lifesciences' share price has fallen 16.5% over the past year, +7.5% over three months and +4.0% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Nectar Lifesciences?

As of 30 Jun 2026: promoters 51.84%, foreign institutions 0.50%, domestic institutions 3.74%, non-institutions 43.89%.

### Who are Nectar Lifesciences' competitors?

The listed Pharma & Healthcare companies closest to Nectar Lifesciences by market cap are Nath Bio-Genes (India), BDH Industries, Hannah Joseph, Syschem (India), Achyut Health and Coral Labs.

### Is Nectar Lifesciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Nectar Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NECLIFE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.